乳腺癌的治疗策略与生存结果
Treatment Strategies and Survival Outcomes in Breast Cancer.
作者信息
Cheung Kwok-Leung
机构信息
School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby DE22 3DT, UK.
出版信息
Cancers (Basel). 2020 Mar 20;12(3):735. doi: 10.3390/cancers12030735.
Abstract
Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient [...].
摘要
乳腺癌的治疗策略广泛多样，通常基于多模式方法，这取决于肿瘤的分期、生物学特性以及患者的接受程度和耐受性[……]
相似文献
1
Treatment Strategies and Survival Outcomes in Breast Cancer.乳腺癌的治疗策略与生存结果
Cancers (Basel). 2020 Mar 20;12(3):735. doi: 10.3390/cancers12030735.
2
[Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].[局部晚期非炎性乳腺癌的联合化疗及术前放疗治疗：120例患者的最新结果]
Cancer Radiother. 2004 Jun;8(3):155-67. doi: 10.1016/j.canrad.2004.01.001.
3
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
4
The increasing efficacy of breast cancer treatment.乳腺癌治疗效果的不断提高。
Clin Oncol (R Coll Radiol). 1997;9(5):338-42. doi: 10.1016/s0936-6555(05)80069-x.
5
Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer.对肿瘤直径大于3厘米的Ⅱ期患者或局部晚期非炎性乳腺癌患者进行原发性化疗和术前放疗。
Radiother Oncol. 1997 Mar;42(3):219-29. doi: 10.1016/s0167-8140(97)01923-3.
6
Influence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites.“诊断延迟”对癌症生存率的影响：五个肿瘤部位的分析。
J Epidemiol Community Health. 1991 Sep;45(3):225-30. doi: 10.1136/jech.45.3.225.
7
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
8
Effect of longer health service provider delays on stage at diagnosis and mortality in symptomatic breast cancer.医疗服务提供者较长时间的延误对有症状乳腺癌诊断分期及死亡率的影响。
Breast. 2015 Jun;24(3):248-55. doi: 10.1016/j.breast.2015.02.027. Epub 2015 Mar 7.
9
Analysis of a large number of clinical studies for breast cancer radiotherapy: estimation of radiobiological parameters for treatment planning.大量乳腺癌放射治疗临床研究分析：治疗计划中放射生物学参数的估计
Phys Med Biol. 2003 Oct 21;48(20):3307-26. doi: 10.1088/0031-9155/48/20/004.
10
Adjuvant chemotherapy for breast cancer--"one fits all"?乳腺癌辅助化疗——“一刀切”可行吗？
Breast. 2005 Dec;14(6):564-9. doi: 10.1016/j.breast.2005.08.020. Epub 2005 Oct 21.
引用本文的文献
1
Treatment outcomes and the associated factors among breast cancer patients in Tanzania: a retrospective cohort study.坦桑尼亚乳腺癌患者的治疗结果及相关因素：一项回顾性队列研究。
Ecancermedicalscience. 2025 Mar 18;19:1874. doi: 10.3332/ecancer.2025.1874. eCollection 2025.
2
Advancing Breast Cancer Research Through Collaborative Computing: Harnessing Google Colab for Innovation.通过协作计算推进乳腺癌研究：利用谷歌Colab实现创新。
Cureus. 2024 Mar 30;16(3):e57280. doi: 10.7759/cureus.57280. eCollection 2024 Mar.
3
Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories.靶向乳腺癌：已知领域、新兴领域与未知领域
Biomolecules. 2023 Aug 25;13(9):1306. doi: 10.3390/biom13091306.
4
Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating Disease-Free and Overall Survival.浸润性乳腺癌中的高凝状态与治疗后低纤溶状态：一项评估无病生存期和总生存期的七年随访研究
Life (Basel). 2023 Apr 28;13(5):1106. doi: 10.3390/life13051106.
5
Viv. Exerts Promising Antitumor Activity against Breast Cancer Cells and Anti-Inflammatory Effects in LPS-Stimulated RAW 264.7 Cells.Viv. 对乳腺癌细胞表现出有前景的抗肿瘤活性，并对 LPS 刺激的 RAW 264.7 细胞具有抗炎作用。
Int J Mol Sci. 2022 Oct 25;23(21):12885. doi: 10.3390/ijms232112885.
6
Mesothelin‑specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3‑treated self‑differentiated dendritic cells.经 40s 核糖体蛋白亚基 3 处理的自分化树突状细胞增强了间皮素特异性 T 细胞对三阴性乳腺癌的细胞毒性。
Oncol Rep. 2022 Jul;48(1). doi: 10.3892/or.2022.8338. Epub 2022 May 26.
7
KIF18B promotes breast cancer cell proliferation, migration and invasion by targeting TRIP13 and activating the Wnt/β-catenin signaling pathway.KIF18B通过靶向TRIP13并激活Wnt/β-连环蛋白信号通路促进乳腺癌细胞的增殖、迁移和侵袭。
Oncol Lett. 2022 Apr;23(4):112. doi: 10.3892/ol.2022.13232. Epub 2022 Feb 8.
8
Treatment outcomes and its associated factors among breast cancer patients at Kitui Referral Hospital.基图伊转诊医院乳腺癌患者的治疗结果及其相关因素。
SAGE Open Med. 2022 Jan 8;10:20503121211067857. doi: 10.1177/20503121211067857. eCollection 2022.
9
Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature.天然产物通过纳米载体的药物递送用于有效的乳腺癌治疗：文献综述。
Int J Nanomedicine. 2021 Dec 2;16:7891-7941. doi: 10.2147/IJN.S328135. eCollection 2021.
10
Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients.乳腺癌患者蛋白酶体 26S 亚基非 ATP 酶（PSMD）家族基因的预后和免疫浸润特征。
Aging (Albany NY). 2021 Nov 28;13(22):24882-24913. doi: 10.18632/aging.203722.
本文引用的文献
1
Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age.细胞质周期蛋白E是70岁以上女性侵袭性肿瘤生物学和乳腺癌特异性死亡率的独立标志物。
Cancers (Basel). 2020 Mar 18;12(3):712. doi: 10.3390/cancers12030712.
2
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.组蛋白去乙酰化酶5抑制剂作为治疗患乳腺癌的极年轻女性的潜在疗法
Cancers (Basel). 2020 Feb 10;12(2):412. doi: 10.3390/cancers12020412.
3
Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation.对患有单侧乳腺癌的女性进行对侧预防性乳房切除术，这些女性为基因携带者、有强烈家族病史或初诊时年龄较轻。
Cancers (Basel). 2020 Jan 6;12(1):140. doi: 10.3390/cancers12010140.
4
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.所有激素受体阳性、人表皮生长因子受体2阴性的转移性乳腺癌患者都应接受细胞周期蛋白依赖性激酶4/6（CDK 4/6）抑制剂作为一线基础治疗吗？一项基于PALOMA 2、MONALEESA 2、MONALEESA 7、MONARCH 3、FALCON、SWOG和FACT试验数据的网状Meta分析。
Cancers (Basel). 2019 Oct 26;11(11):1661. doi: 10.3390/cancers11111661.
5
Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer.两项基于大型人群队列的乳腺癌和结直肠癌患者的总生存率及治疗模式趋势
Cancers (Basel). 2019 Aug 23;11(9):1239. doi: 10.3390/cancers11091239.
6
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker.乳酸脱氢酶（LDH）对一线治疗的反应可预测转移性乳腺癌的生存情况：关于一种具有成本效益的动态生物标志物的初步线索
Cancers (Basel). 2019 Aug 24;11(9):1243. doi: 10.3390/cancers11091243.
7
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.ERCC1是早期或局部晚期乳腺癌中蒽环类药物耐药和紫杉烷敏感性的预测指标。
Cancers (Basel). 2019 Aug 10;11(8):1149. doi: 10.3390/cancers11081149.
8
Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer.导管原位癌及同步浸润性乳腺癌中的基因表达
Cancers (Basel). 2019 Jul 27;11(8):1062. doi: 10.3390/cancers11081062.
9
Exercise Intervention Improves Clinical Outcomes, but the "Time of Session" is Crucial for Better Quality of Life in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.运动干预可改善临床结局，但“训练时间”对提高乳腺癌幸存者的生活质量至关重要：一项系统评价与荟萃分析
Cancers (Basel). 2019 May 22;11(5):706. doi: 10.3390/cancers11050706.
10
Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study.淋巴结比率在接受保乳治疗的pN1期乳腺癌患者锁骨上淋巴结放射治疗决策中的临床意义（KROG 14 - 18）：一项多中心研究
Cancers (Basel). 2019 May 16;11(5):680. doi: 10.3390/cancers11050680.
Zotero 插件